ArticleJournal of contemporary brachytherapy2026
Outcomes of cervical carcinoma patients treated with chemoradiation and single-application two-fractions schedule of high-dose-rate brachytherapy: A retrospective review (SATF study).
Article in Journal of contemporary brachytherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Brachytherapy remains integral component in curative-intent management of locally advanced cervical cancer, with overall treatment time (OTT) strongly influencing outcomes. In this study, we intended to analyze single-application two-fraction (SATF) high-dose-rate (HDR) brachytherapy feasibility, treatment outcomes, and toxicities. Material and methods: This study included 238 patients with stage IB-IVA (FIGO 2018) cervical cancer treated with definitive external beam chemoradiation 45 Gray (Gy) in 25 fractions and concurrent weekly cisplatin, followed by SATF HDR brachytherapy (7 Gy × 4 fractions in two applications, ≥ 12 hours apart) between April 2020 and December 2022. Primary endpoint was 3-year disease-free survival (DFS), while secondary endpoints were 3-year overall survival (OS), local control (LC), and acute/late toxicities (as per RTOG criteria). Results: Out of 238 treated patients, majority of them had squamous cell carcinoma (96.6%) and locally advanced disease (stage IIB: 47.5%, IIIC1r: 28.2%). Intracavitary brachytherapy was used in 89.5% of cases. The mean EQD Conclusions: SATF HDR brachytherapy with chemoradiation offers favorable disease control and acceptable late toxicities, with good dosimetry while optimizing OTT in cervical cancer management. This approach is feasible and especially effective in high-volume, resource-constrained LMIC settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.